Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 296

1.

Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD.

Rocnik JL, Okabe R, Yu JC, Lee BH, Giese N, Schenkein DP, Gilliland DG.

Blood. 2006 Aug 15;108(4):1339-45.

2.

Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.

Li L, Piloto O, Nguyen HB, Greenberg K, Takamiya K, Racke F, Huso D, Small D.

Blood. 2008 Apr 1;111(7):3849-58. doi: 10.1182/blood-2007-08-109942.

3.

Tyk2 is dispensable for induction of myeloproliferative disease by mutant FLT3.

Nakajima H, Shibata F, Kumagai H, Shimoda K, Kitamura T.

Int J Hematol. 2006 Jul;84(1):54-9.

PMID:
16867903
4.

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo.

Nabinger SC, Li XJ, Ramdas B, He Y, Zhang X, Zeng L, Richine B, Bowling JD, Fukuda S, Goenka S, Liu Z, Feng GS, Yu M, Sandusky GE, Boswell HS, Zhang ZY, Kapur R, Chan RJ.

Leukemia. 2013 Feb;27(2):398-408. doi: 10.1038/leu.2012.308.

5.

FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

Grundler R, Miething C, Thiede C, Peschel C, Duyster J.

Blood. 2005 Jun 15;105(12):4792-9.

6.

FLT3/ITD mutation signaling includes suppression of SHP-1.

Chen P, Levis M, Brown P, Kim KT, Allebach J, Small D.

J Biol Chem. 2005 Feb 18;280(7):5361-9.

7.

FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation.

Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K, Nagafuji K, Mizuno S, Niiro H, Gilliland GD, Akashi K.

Blood. 2009 Dec 3;114(24):5034-43. doi: 10.1182/blood-2008-12-196055.

8.

AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.

Barbarroja N, Torres LA, Rodriguez-Ariza A, Valverde-Estepa A, Lopez-Sanchez LM, Ruiz-Limon P, Perez-Sanchez C, Carretero RM, Velasco F, López-Pedrera C.

Exp Hematol. 2010 Aug;38(8):641-52. doi: 10.1016/j.exphem.2010.03.017.

PMID:
20380868
9.

Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).

Murata K, Kumagai H, Kawashima T, Tamitsu K, Irie M, Nakajima H, Suzu S, Shibuya M, Kamihira S, Nosaka T, Asano S, Kitamura T.

J Biol Chem. 2003 Aug 29;278(35):32892-8.

10.

Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation.

Rausei-Mills V, Chang KL, Gaal KK, Weiss LM, Huang Q.

Am J Clin Pathol. 2008 Apr;129(4):624-9. doi: 10.1309/NRTX9AKXHR5JBT93.

11.

Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.

Reindl C, Bagrintseva K, Vempati S, Schnittger S, Ellwart JW, Wenig K, Hopfner KP, Hiddemann W, Spiekermann K.

Blood. 2006 May 1;107(9):3700-7.

12.

NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia.

Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow C, Duyster J, Tenen DG, Niederwieser D, Behre G.

Leukemia. 2015 Mar;29(3):535-47. doi: 10.1038/leu.2014.231.

13.

Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.

Vempati S, Reindl C, Wolf U, Kern R, Petropoulos K, Naidu VM, Buske C, Hiddemann W, Kohl TM, Spiekermann K.

Clin Cancer Res. 2008 Jul 15;14(14):4437-45. doi: 10.1158/1078-0432.CCR-07-1873.

14.

SRC is a signaling mediator in FLT3-ITD- but not in FLT3-TKD-positive AML.

Leischner H, Albers C, Grundler R, Razumovskaya E, Spiekermann K, Bohlander S, Rönnstrand L, Götze K, Peschel C, Duyster J.

Blood. 2012 Apr 26;119(17):4026-33. doi: 10.1182/blood-2011-07-365726.

15.

Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.

Takahashi S, Harigae H, Yokoyama H, Ishikawa I, Abe S, Imaizumi M, Sasaki T, Kaku M.

Int J Hematol. 2006 Oct;84(3):256-61.

PMID:
17050201
16.

Constitutive activation of Flt3 and STAT5A enhances self-renewal and alters differentiation of hematopoietic stem cells.

Moore MA, Dorn DC, Schuringa JJ, Chung KY, Morrone G.

Exp Hematol. 2007 Apr;35(4 Suppl 1):105-16.

PMID:
17379095
17.

Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.

Spiekermann K, Bagrintseva K, Schwab R, Schmieja K, Hiddemann W.

Clin Cancer Res. 2003 Jun;9(6):2140-50.

18.

A role of Gab2 association in Flt3 ITD mediated Stat5 phosphorylation and cell survival.

Masson K, Liu T, Khan R, Sun J, Rönnstrand L.

Br J Haematol. 2009 Jul;146(2):193-202. doi: 10.1111/j.1365-2141.2009.07725.x.

PMID:
19438505
19.

MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.

Nishioka C, Ikezoe T, Yang J, Takeuchi S, Koeffler HP, Yokoyama A.

Leuk Res. 2008 Sep;32(9):1382-92. doi: 10.1016/j.leukres.2008.02.018.

PMID:
18394702
20.
Items per page

Supplemental Content

Support Center